title: Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers.
abstract: Clostridium perfringens enterotoxin (CPE) is a three-domain polypeptide, which binds to Claudin-3 and Claudin-4 with high affinity. Because these receptors are highly differentially expressed in many human tumors, claudin-3 and claudin-4 may provide an efficient molecular tool to specifically identify and target biologically aggressive human cancer cells for CPE-specific binding and cytolysis. In this review we will discuss these surface proteins as targets for the detection and treatment of chemotherapy-resistant gynecologic malignancies overexpressing claudin-3 and -4 using CPE-based theranostic agents. We will also discuss the use of fluorescent c-CPE peptide in the operative setting for real time detection of micro-metastatic tumors during surgery and review the potential role of CPE in other medical applications.
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA. jonathan.black@yale.edu.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Black
authors.affiliation: Division of Gynecologic Oncology, University Campus Bio-Medico of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy. s.lopez@unicampus.it.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Lopez
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA. emiliano.cocco@yale.edu.
authors.forename: Emiliano
authors.initials: E
authors.lastname: Cocco
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA. carlton.schwab@yale.edu.
authors.forename: Carlton L
authors.initials: CL
authors.lastname: Schwab
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA. diana.english@yale.edu.
authors.forename: Diana P
authors.initials: DP
authors.lastname: English
authors.affiliation: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT 06520-8063, USA. alessandro.santin@yale.edu.
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Santin
mesh_terms: D000818:Animals; D001665:Binding Sites; D062465:Claudin-3 / Q000378:metabolism; D062506:Claudin-4 / Q000378:metabolism; D004768:Enterotoxins / Q000627:therapeutic use*; D005260:Female; D005833:Genital Neoplasms, Female / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D017434:Protein Structure, Tertiary
chemical_list: D062465:Claudin-3; D062506:Claudin-4; D004768:Enterotoxins; C035598:enterotoxin, Clostridium
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1065-74
references.pmid: 21123456
references.citation: Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):805-7
references.pmid: 8456884
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1069-74
references.pmid: 19139430
references.citation: Prostate. 2012 Mar;72(4):351-60
references.pmid: 21656836
references.citation: J Bacteriol. 2006 Feb;188(4):1585-98
references.pmid: 16452442
references.citation: Int J Mol Sci. 2013;14(5):10412-37
references.pmid: 23685873
references.citation: Cancer Res. 2003 Oct 1;63(19):6265-71
references.pmid: 14559813
references.citation: J Cell Biol. 1997 Mar 24;136(6):1239-47
references.pmid: 9087440
references.citation: Int J Cancer. 2004 Oct 20;112(1):14-25
references.pmid: 15305371
references.citation: Nat Med. 2011 Oct;17(10):1315-9
references.pmid: 21926976
references.citation: Clin Infect Dis. 1997 Sep;25 Suppl 2:S165-7
references.pmid: 9310665
references.citation: Ann Oncol. 2012 Feb;23(2):346-52
references.pmid: 21562072
references.citation: Toxicon. 1996 Nov-Dec;34(11-12):1335-43
references.pmid: 9027990
references.citation: J Cell Biol. 1998 Jun 29;141(7):1539-50
references.pmid: 9647647
references.citation: Mol Cell Proteomics. 2006 Mar;5(3):433-43
references.pmid: 16319398
references.citation: MBio. 2013;4(1). pii: e00594-12. doi: 10.1128/mBio.00594-12
references.pmid: 23322640
references.citation: Gastroenterology. 2001 Sep;121(3):678-84
references.pmid: 11522752
references.citation: Virchows Arch. 2007 Sep;451(3):669-80
references.pmid: 17609977
references.citation: Anaerobe. 2004 Apr;10(2):107-14
references.pmid: 16701507
references.citation: BMC Cancer. 2010;10:349
references.pmid: 20598131
references.citation: Cancer Res. 2001 Nov 1;61(21):7878-81
references.pmid: 11691807
references.citation: Neoplasia. 2007 Apr;9(4):304-14
references.pmid: 17460774
references.citation: J Biol Chem. 1991 Jun 15;266(17):11037-43
references.pmid: 1645721
references.citation: Infect Immun. 1997 Mar;65(3):1014-22
references.pmid: 9038311
references.citation: Hum Pathol. 2004 Dec;35(12):1531-6
references.pmid: 15619213
references.citation: PLoS One. 2013;8(9):e74994
references.pmid: 24069372
references.citation: Lancet. 2002 Aug 17;360(9332):505-15
references.pmid: 12241653
references.citation: Oncologist. 2000;5(1):26-35
references.pmid: 10706647
references.citation: Clin Cancer Res. 2007 Jun 1;13(11):3339-46
references.pmid: 17545541
references.citation: Appl Immunohistochem Mol Morphol. 2014;22(2):125-31
references.pmid: 23702644
references.citation: Am J Pathol. 2004 May;164(5):1627-33
references.pmid: 15111309
references.citation: Cancer. 2011 Dec 15;117(24):5519-28
references.pmid: 21692061
references.citation: Cancer Res. 2005 Nov 1;65(21):9603-6
references.pmid: 16266975
references.citation: Anticancer Res. 2011 Apr;31(4):1271-7
references.pmid: 21508375
references.citation: J Med Assoc Thai. 2006 Mar;89(3):275-82
references.pmid: 16696408
references.citation: Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):511-6
references.pmid: 9892664
references.citation: Brain Pathol. 2010 Jan;20(1):140-50
references.pmid: 19220299
references.citation: Infect Immun. 1996 Mar;64(3):1020-5
references.pmid: 8641752
references.citation: Oncogenesis. 2012 Nov 12;1:e33
references.pmid: 23552466
references.citation: Cancer Res. 2005 May 15;65(10):4334-42
references.pmid: 15899825
references.citation: Cancer Res. 2007 Sep 1;67(17):7977-82
references.pmid: 17804705
references.citation: Drugs. 2011 Jul 30;71(11):1397-412
references.pmid: 21812505
references.citation: Oncologist. 2010;15(10):1026-33
references.pmid: 20930101
references.citation: Gene Ther. 2012 May;19(5):494-503
references.pmid: 21975465
references.citation: Compr Physiol. 2012 Jul;2(3):1819-52
references.pmid: 23723025
references.citation: Cancer Chemother Pharmacol. 1986;18(3):280-3
references.pmid: 3802384
references.citation: Biol Pharm Bull. 2006 Sep;29(9):1783-9
references.pmid: 16946486
references.citation: J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9
references.pmid: 12953086
references.citation: Curr Opin Oncol. 2006 Sep;18(5):494-9
references.pmid: 16894299
references.citation: J Biol Chem. 1997 Oct 17;272(42):26652-8
references.pmid: 9334247
references.citation: Mol Cancer Ther. 2009 Jul;8(7):1906-15
references.pmid: 19567823
references.citation: Pharmacol Rev. 2012 Jul;64(3):706-21
references.pmid: 22659329
references.citation: FEBS Lett. 2000 Jul 7;476(3):258-61
references.pmid: 10913624
references.citation: Cancer Res. 2000 Nov 15;60(22):6281-7
references.pmid: 11103784
references.citation: Br J Cancer. 2005 Apr 25;92(8):1561-73
references.pmid: 15785748
references.citation: Clin Obstet Gynecol. 1994 Jun;37(2):377-91
references.pmid: 8033450